Michael Mahoney officially assumes the title of CEO at Boston Scientific (BSX) today after...


Michael Mahoney officially assumes the title of CEO at Boston Scientific (BSX) today after serving for a year as president following his departure from Johnson & Johnson, which basically allowed him to get round a non-compete agreement. Mahoney succeeds interim CEO William Kucheman.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs